Biotech ETFs Gain Momentum via AI Drug Discovery & Surging M&A

Biotech ETFs are surging as the sector breaks out of a multiyear bear market, helped by moderating macro headwinds and a more stable regulatory backdrop. The article signals a constructive shift in sentiment and positioning for healthcare and biotech, though it does not cite specific price moves or company-level catalysts.

Analysis

Biotech ETFs are surging as the sector breaks out of a multiyear bear market, helped by moderating macro headwinds and a more stable regulatory backdrop. The article signals a constructive shift in sentiment and positioning for healthcare and biotech, though it does not cite specific price moves or company-level catalysts.